PL332565A1 - Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases - Google Patents

Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases

Info

Publication number
PL332565A1
PL332565A1 PL99332565A PL33256599A PL332565A1 PL 332565 A1 PL332565 A1 PL 332565A1 PL 99332565 A PL99332565 A PL 99332565A PL 33256599 A PL33256599 A PL 33256599A PL 332565 A1 PL332565 A1 PL 332565A1
Authority
PL
Poland
Prior art keywords
spla
tricyclic compounds
soothing
drug
production
Prior art date
Application number
PL99332565A
Other languages
English (en)
Inventor
Benjamin Alan Anderson
Nicholas James Bach
Jolie Anne Bastian
Nancy Kay Harn
Richard Waltz Harper
Gary Alan Hite
Michael Dean Kinnick
Ho-Shen Lin
Richard James Loncharich
Mcgill John Mcneill Iii
Edward Dawid Mihelich
John Michael Morin
Michael Leroy Phillips
Michael Enrico Richett
Daniel Jon Sall
Jason Scott Sawyer
Richard Walter Schevitz
Robert Theodore Vasileff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL332565A1 publication Critical patent/PL332565A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL99332565A 1998-04-17 1999-04-16 Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases PL332565A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
PL332565A1 true PL332565A1 (en) 1999-10-25

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
PL99332565A PL332565A1 (en) 1998-04-17 1999-04-16 Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases
PL99332566A PL332566A1 (en) 1998-04-17 1999-04-16 Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, method of treating such diseases, novel intermediate compounds, method of obtaining tricyclic compounds and application of tricyclic compounds in production of a drug

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL99332566A PL332566A1 (en) 1998-04-17 1999-04-16 Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, method of treating such diseases, novel intermediate compounds, method of obtaining tricyclic compounds and application of tricyclic compounds in production of a drug

Country Status (30)

Country Link
EP (2) EP0952149B1 (enExample)
JP (2) JPH11322713A (enExample)
KR (2) KR100586761B1 (enExample)
CN (1) CN1149193C (enExample)
AR (2) AR018186A1 (enExample)
AT (2) ATE268756T1 (enExample)
AU (2) AU753547B2 (enExample)
BR (2) BR9902365A (enExample)
CA (2) CA2269262A1 (enExample)
CO (2) CO5011054A1 (enExample)
CZ (2) CZ137099A3 (enExample)
DE (2) DE69917833T2 (enExample)
DK (1) DK0950657T3 (enExample)
DZ (1) DZ2769A1 (enExample)
EA (2) EA002347B1 (enExample)
ES (2) ES2222663T3 (enExample)
HU (2) HUP9901221A3 (enExample)
ID (2) ID23761A (enExample)
IL (2) IL129485A0 (enExample)
NO (2) NO312240B1 (enExample)
NZ (3) NZ507564A (enExample)
PE (2) PE20000432A1 (enExample)
PL (2) PL332565A1 (enExample)
PT (1) PT950657E (enExample)
SG (2) SG81977A1 (enExample)
SI (1) SI0950657T1 (enExample)
TR (2) TR199900843A2 (enExample)
TW (1) TWI238160B (enExample)
YU (2) YU18999A (enExample)
ZA (2) ZA992772B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
CA2358492A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
DE60032774D1 (de) * 1999-07-19 2007-02-15 Lilly Co Eli Spla2 inhibitoren
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
DE60130891T2 (de) * 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo Heilmittel für krebs
WO2002000256A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
WO2002000257A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for alzheimer's disease
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
AU2002239263A1 (en) 2000-12-18 2002-07-01 Eli Lilly And Company Tetracyclic carbazole derivates and their use as spla2 inhibitors
DE60218155D1 (de) 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
WO2009119534A1 (ja) 2008-03-26 2009-10-01 第一三共株式会社 新規テトラヒドロイソキノリン誘導体
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US8580795B2 (en) 2009-01-22 2013-11-12 Orchid Chemicals & Pharmaceuticals Limited Heterocyclic compounds as phosphodiesterase inhibitors
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
WO2014083163A1 (en) 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
RU2015118217A (ru) 2012-11-30 2017-01-11 ДжиИ ХЕЛТКЕР ЛИМИТЕД Способ кристаллизации трициклических индольных производных
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
JPH06509087A (ja) * 1991-07-05 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
DE69614232T2 (de) * 1995-12-13 2002-01-10 Eli Lilly And Co., Indianapolis Naphthyl-Acetamide als sPLA2-Inhibitoren
KR20000049210A (ko) * 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
JP2001522884A (ja) * 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
PE20000476A1 (es) 2000-06-02
EP0952149B1 (en) 2004-06-09
DE69918590D1 (de) 2004-08-19
NO314400B1 (no) 2003-03-17
NZ335251A (en) 2000-11-24
ES2222663T3 (es) 2005-02-01
YU18999A (sh) 2002-08-12
CO5011054A1 (es) 2001-02-28
NZ335253A (en) 2000-11-24
BR9902365A (pt) 2001-04-24
TR199900843A2 (xx) 2000-02-21
NZ507564A (en) 2002-10-25
AU753436B2 (en) 2002-10-17
ES2226286T3 (es) 2005-03-16
EP0950657A2 (en) 1999-10-20
AR018186A1 (es) 2001-10-31
HU9901220D0 (en) 1999-06-28
HUP9901221A3 (en) 2001-11-28
ATE271037T1 (de) 2004-07-15
AU753547B2 (en) 2002-10-24
CO5031247A1 (es) 2001-04-27
TWI238160B (en) 2005-08-21
EA199900301A3 (ru) 2000-04-24
CZ137099A3 (cs) 1999-11-17
PL332566A1 (en) 1999-10-25
EA199900301A2 (ru) 1999-10-28
HUP9901220A3 (en) 2001-11-28
NO312240B1 (no) 2002-04-15
DZ2769A1 (fr) 2003-12-01
HU9901221D0 (en) 1999-06-28
ZA992771B (en) 2002-04-18
ID23287A (id) 2000-04-05
JP4435330B2 (ja) 2010-03-17
DK0950657T3 (da) 2004-11-22
PE20000432A1 (es) 2000-05-23
DE69917833D1 (de) 2004-07-15
AU2381799A (en) 1999-10-28
NO991821L (no) 1999-10-18
TR199900853A3 (tr) 1999-11-22
SI0950657T1 (en) 2005-02-28
IL129485A0 (en) 2000-02-29
ZA992772B (en) 2002-07-16
CA2269262A1 (en) 1999-10-17
SG81976A1 (en) 2001-07-24
KR19990083233A (ko) 1999-11-25
HU9901221A (hu) 2000-04-28
BR9901279A (pt) 2000-05-02
JPH11322713A (ja) 1999-11-24
KR100586761B1 (ko) 2006-06-08
TR199900853A2 (xx) 1999-11-22
NO991822D0 (no) 1999-04-16
EA002816B1 (ru) 2002-10-31
CN1253948A (zh) 2000-05-24
IL129483A0 (en) 2000-02-29
AR018593A1 (es) 2001-11-28
DE69918590T2 (de) 2005-07-21
EP0950657A3 (en) 2001-08-16
CZ136999A3 (cs) 1999-11-17
JP2000026416A (ja) 2000-01-25
DE69917833T2 (de) 2005-07-14
PT950657E (pt) 2004-11-30
AU2381999A (en) 1999-10-28
CA2269246A1 (en) 1999-10-17
NO991821D0 (no) 1999-04-16
KR19990083232A (ko) 1999-11-25
YU19199A (sh) 2002-08-12
SG81977A1 (en) 2001-07-24
CA2269246C (en) 2009-08-25
EA199900303A2 (ru) 1999-10-28
NO991822L (no) 1999-10-18
EA199900303A3 (ru) 2000-04-24
ATE268756T1 (de) 2004-06-15
CN1149193C (zh) 2004-05-12
EA002347B1 (ru) 2002-04-25
EP0952149A2 (en) 1999-10-27
EP0952149A3 (en) 2001-08-16
HU9901220A (hu) 2000-04-28
EP0950657B1 (en) 2004-07-14
ID23761A (id) 2000-05-11

Similar Documents

Publication Publication Date Title
PL332566A1 (en) Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, method of treating such diseases, novel intermediate compounds, method of obtaining tricyclic compounds and application of tricyclic compounds in production of a drug
PL332564A1 (en) Novel tricyclic compounds, spla inhibiting method, method of soothing pathological consequences of diseases associated with spla, application of tricyclic compounds in production of a drug and method of treating diseases
PL333118A1 (en) Pharmaceutical product method of sexual disease treatment and method of manufacturing of this pharmaceutical product
EP1100508B8 (en) Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
HUP9600834A1 (en) Quinazoline derivatives, producing and using them for the treatment of hyperproliferative diseases in a mammal, and a pharmaceutical composition containing the compounds
AU2003235613A1 (en) Crude drug compositions for treating or preventing arthritic diseases and the preparation process
PL339489A1 (en) Pre-filled ampoules and their production
HUP0104909A3 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity, process for their preparation and medicaments containing them
SK7822003A3 (en) Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
HU9904392D0 (en) New derivatives of erythromycin, process for their production and their use as medicament
HUP0104116A3 (en) Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
HUP9903950A3 (en) Improved process for the production of bisphenols
PL311257A1 (en) New compounds and method of their production as well as pharmaceutical compounds and method of its production
DE69803190D1 (de) Einteiliges schwungrad mit aüsserem, verzahntem ring und dessen herstellungsverfahren
PL308074A1 (en) Derivatives of borone peptides, their production as well as their application in medical therapy
PL312693A1 (en) Oxathiolanes, method of their production and pharmaceutical compounds containing them
IL139817A0 (en) Non-hydrated gabapentin polymorph, a process for the preparation thereof and the use thereof for the preparation of pharmaceutical grade gabapentin
MXPA02009434A (es) Formulacion medicinal para la estimulacion de la leucopoyesis para el tratamiento de enfermedades tumorales y de protozoos, de acarinosis, artropodiasis y un procedimiento para su preparacion.
IL141501A0 (en) Alginate capsules for use in the treatment of brain tumour
AU6126498A (en) Method for the treatment of drug addiction and homeopathic remedy
HUP0203443A3 (en) Novel contraceptive medicament and method for producing the same
IL153439A0 (en) Medicines for the prevention and treatment of neurodegenerative diseases
PL326844A1 (en) Novel derivatives of quinosalinodione, their production and implementation in drugs

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)